Minding the gap – AI regulators should learn from the pharmaceutical industry
AI leaders are warning of catastrophe, but regulations remain limited. The history of the pharmaceutical industry shows why we shouldn’t wait... The post Minding the gap – AI regulators should learn from the pharmaceutical industry appeared first on Cancer Research UK - Cancer News .
Leaders in artificial intelligence warn of potential catastrophe, yet regulations remain limited. The pharmaceutical industry offers valuable lessons for policymakers grappling with how to regulate AI. Once unregulated, the pharmaceutical industry underwent significant changes after the thalidomide disaster, which resulted in over 10,000 birth defects.
This tragedy prompted the UK government to enact the Medicines Act 1968, introducing stricter testing before medicines reached patients. The pharmaceutical industry now requires rigorous testing and reliable evidence, which helps drive innovation without hindering it, and remains highly profitable. Policymakers should learn from the pharmaceutical industry's experience, emphasizing the importance of independent assessment and continual monitoring to ensure safety while fostering progress.
Written by urgent.news from Cancer Research UK's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
